|
|
|
1 |
(84) |
|
|
|
2 |
(2) |
|
|
|
2 |
(1) |
|
|
|
2 |
(1) |
|
|
|
3 |
(1) |
|
|
|
3 |
(1) |
|
|
Consolidation---General Recognition |
|
|
3 |
(1) |
|
|
|
3 |
(1) |
|
|
|
4 |
(1) |
|
|
Drug and Active Principle |
|
|
4 |
(1) |
|
|
The Aims of Isolating Active Principles |
|
|
4 |
(2) |
|
|
Plants as Sources of Effective Medicines |
|
|
6 |
(2) |
|
|
|
8 |
(2) |
|
|
Congeneric Drugs and Name Diversity |
|
|
10 |
(2) |
|
|
|
12 |
(1) |
|
|
|
12 |
(2) |
|
|
Drug Administration by Inhalation |
|
|
14 |
(2) |
|
|
|
16 |
(2) |
|
|
|
16 |
(1) |
|
|
Dermatological Agents as Vehicles |
|
|
16 |
(2) |
|
|
From Administration to Distribution in the Body |
|
|
18 |
(2) |
|
|
|
20 |
(1) |
|
|
Potential Targets of Drug Action |
|
|
20 |
(2) |
|
|
|
22 |
(1) |
|
|
External Barriers of the Body |
|
|
22 |
(2) |
|
|
|
24 |
(2) |
|
|
|
26 |
(2) |
|
|
|
28 |
(2) |
|
|
Possible Modes of Drug Distribution |
|
|
30 |
(2) |
|
|
Binding to Plasma Proteins |
|
|
32 |
(2) |
|
|
|
34 |
(1) |
|
|
The Liver as an Excretory Organ |
|
|
34 |
(2) |
|
|
Biotransformation of Drugs |
|
|
36 |
(2) |
|
|
Drug Metabolism by Cytochrome P450 |
|
|
38 |
(2) |
|
|
Enterohepatic Circulation |
|
|
40 |
(1) |
|
|
|
40 |
(2) |
|
|
The Kidney as an Excretory Organ |
|
|
42 |
(2) |
|
|
|
44 |
(2) |
|
|
|
46 |
(1) |
|
|
Drug Concentration in the Body as a Function of Time---First Order (Exponential) Rate Processes |
|
|
46 |
(2) |
|
|
Time Course of Drug Concentration in Plasma |
|
|
48 |
(2) |
|
|
Time Course of Drug Plasma Levels during Repeated Dosing |
|
|
50 |
(1) |
|
|
Time Course of Drug Plasma Levels during Irregular Intake |
|
|
50 |
(2) |
|
|
Accumulation: Dose, Dose Interval, and Plasma Level Fluctuation |
|
|
52 |
(1) |
|
|
Change in Elimination Characteristics during Drug Therapy |
|
|
52 |
(2) |
|
|
Quantification of Drug Action |
|
|
54 |
(1) |
|
|
Dose-Response Relationship |
|
|
54 |
(2) |
|
|
Concentration-Effect Relationship |
|
|
56 |
(1) |
|
|
Concentration-Effect Curves |
|
|
56 |
(2) |
|
|
Drug-Receptor Interaction |
|
|
58 |
(1) |
|
|
Concentration-Binding Curves |
|
|
58 |
(2) |
|
|
|
60 |
(2) |
|
|
|
60 |
(1) |
|
|
|
60 |
(2) |
|
|
|
62 |
(1) |
|
|
Models of the Molecular Mechanism of Agonist/Antagonist Action |
|
|
62 |
(1) |
|
|
Other Forms of Antagonism |
|
|
62 |
(2) |
|
|
Enantioselectivity of Drug Action |
|
|
64 |
(2) |
|
|
|
66 |
(2) |
|
|
Mode of Operation of G-Protein-coupled Receptors |
|
|
68 |
(2) |
|
|
Time Course of Plasma Concentration and Effect |
|
|
70 |
(2) |
|
|
|
72 |
(1) |
|
|
Adverse Drug Effects, Side Effects |
|
|
72 |
(2) |
|
|
Causes of Adverse Effects |
|
|
72 |
(2) |
|
|
|
74 |
(2) |
|
|
|
76 |
(2) |
|
|
Drug Toxicity in Pregnancy and Lactation |
|
|
78 |
(2) |
|
|
Genetic Variation of Drug Effects |
|
|
80 |
(1) |
|
|
|
80 |
(2) |
|
|
|
82 |
(1) |
|
|
|
82 |
(3) |
|
|
|
85 |
(222) |
|
|
Drugs Acting on the Sympathetic Nervous System |
|
|
86 |
(1) |
|
|
Sympathetic Nervous System |
|
|
86 |
(2) |
|
|
Structure of the Sympathetic Nervous System |
|
|
88 |
(1) |
|
|
|
88 |
(2) |
|
|
Adrenoceptor Subtypes and Catecholamine Actions |
|
|
90 |
(1) |
|
|
|
90 |
(1) |
|
|
|
90 |
(2) |
|
|
|
92 |
(1) |
|
|
|
92 |
(2) |
|
|
Structure-Activity Relationships of Sympathomimetics |
|
|
94 |
(2) |
|
|
Indirect Sympathomimetics |
|
|
96 |
(2) |
|
|
α-Sympathomimetics, α-Sympatholytics |
|
|
98 |
(1) |
|
|
|
98 |
(1) |
|
|
|
98 |
(2) |
|
|
|
100 |
(2) |
|
|
Drugs Acting on the Parasympathetic Nervous System |
|
|
102 |
(1) |
|
|
Parasympathetic Nervous System |
|
|
102 |
(2) |
|
|
|
104 |
(2) |
|
|
|
106 |
(2) |
|
|
|
108 |
(4) |
|
|
|
112 |
(1) |
|
|
|
112 |
(2) |
|
|
Histamine Effects and Their Pharmacological Properties |
|
|
114 |
(2) |
|
|
|
116 |
(2) |
|
|
|
116 |
(1) |
|
|
Promoters of Serotonin Effects |
|
|
116 |
(1) |
|
|
|
116 |
(2) |
|
|
|
118 |
(1) |
|
|
|
118 |
(2) |
|
|
|
120 |
(1) |
|
|
|
120 |
(2) |
|
|
|
122 |
(2) |
|
|
|
124 |
(2) |
|
|
Dihydropyridine Derivatives |
|
|
124 |
(1) |
|
|
Verapamil and Other Catamphiphilic Ca2+ Antagonists |
|
|
124 |
(2) |
|
|
Inhibitors of the Renin-Angiotensin---Aldosterone System |
|
|
126 |
(2) |
|
|
Drugs Acting on Smooth Muscle |
|
|
128 |
(1) |
|
|
Drugs Used to Influence Smooth-Muscle Organs |
|
|
128 |
(2) |
|
|
|
130 |
(2) |
|
|
|
132 |
(2) |
|
|
|
134 |
(2) |
|
|
Drugs for Selective Control of Sinoatrial and AV Nodes |
|
|
134 |
(1) |
|
|
Nonspecific Drug Actions on impulse Generation and Propagation |
|
|
134 |
(2) |
|
|
Electrophysiological Actions of Antiarrhythmics of the Na+ Channel-blocking Type |
|
|
136 |
(2) |
|
|
|
138 |
(1) |
|
|
Drugs for the Treatment of Anemias |
|
|
138 |
(2) |
|
|
|
138 |
(1) |
|
|
|
138 |
(1) |
|
|
|
138 |
(2) |
|
|
|
140 |
(2) |
|
|
|
142 |
(1) |
|
|
Prophylaxis and Therapy of Thrombosis |
|
|
142 |
(2) |
|
|
Vitamin K Antagonists and Vitamin K |
|
|
144 |
(1) |
|
|
Possibilities for Interaction |
|
|
144 |
(2) |
|
|
|
146 |
(1) |
|
|
|
146 |
(2) |
|
|
|
148 |
(2) |
|
|
Inhibitors of Platelet Aggregation |
|
|
150 |
(1) |
|
|
Presystemic Effect of ASA |
|
|
150 |
(2) |
|
|
|
152 |
(2) |
|
|
Drugs Used in Hyperlipoproteinemias |
|
|
154 |
(1) |
|
|
|
154 |
(4) |
|
|
|
158 |
(1) |
|
|
|
158 |
(2) |
|
|
NaCl Reabsorption in the Kidney |
|
|
160 |
(1) |
|
|
|
160 |
(1) |
|
|
|
160 |
(2) |
|
|
Diuretics of the Sulfonamide Type |
|
|
162 |
(2) |
|
|
Potassium-sparing Diuretics |
|
|
164 |
(1) |
|
|
Vasopressin and Derivatives |
|
|
164 |
(2) |
|
|
Water and Electrolyte Disorders |
|
|
166 |
(2) |
|
|
Disorders of Na+ Homeostasis |
|
|
166 |
(1) |
|
|
Disorders of K+ Homeostasis |
|
|
166 |
(2) |
|
|
|
168 |
(1) |
|
|
Therapy of Gastric and Duodenal Ulcers |
|
|
168 |
(1) |
|
|
Treatment of Hyperacidity |
|
|
168 |
(1) |
|
|
|
168 |
(4) |
|
|
|
172 |
(2) |
|
|
Drugs Affecting the Motor System |
|
|
174 |
(1) |
|
|
Drugs Affecting Motor Function |
|
|
174 |
(2) |
|
|
Central Muscle Relaxants and Toxins |
|
|
174 |
(2) |
|
|
|
176 |
(4) |
|
|
Depolarizing Muscle Relaxants |
|
|
176 |
(2) |
|
|
Nondepolarizing Muscle Relaxants |
|
|
178 |
(1) |
|
|
Influencing the Contractile System |
|
|
178 |
(2) |
|
|
Drugs for the Suppression of Pain (Analgesics) |
|
|
180 |
(1) |
|
|
Pain Mechanisms and Pathways |
|
|
180 |
(2) |
|
|
|
182 |
(2) |
|
|
Antipyretic Analgesics vs. NSAIDs |
|
|
184 |
(1) |
|
|
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) |
|
|
184 |
(2) |
|
|
Cyclooxygenase (COX) Inhibitors |
|
|
186 |
(2) |
|
|
|
188 |
(6) |
|
|
|
194 |
(6) |
|
|
Drugs Acting on the Central Nervous System |
|
|
200 |
(1) |
|
|
General Anesthesia and General Anesthetic Drugs |
|
|
200 |
(2) |
|
|
|
202 |
(2) |
|
|
|
204 |
(2) |
|
|
|
206 |
(2) |
|
|
Benzodiazepine Antagonist |
|
|
206 |
(2) |
|
|
Pharmacokinetics of Benzodiazepines |
|
|
208 |
(2) |
|
|
Therapy of Depressive Illness |
|
|
210 |
(4) |
|
|
|
214 |
(2) |
|
|
Agents to Treat Manic States |
|
|
214 |
(2) |
|
|
|
216 |
(4) |
|
|
|
216 |
(4) |
|
|
|
220 |
(1) |
|
|
Hypothalamic and Hypophyseal Hormones |
|
|
220 |
(2) |
|
|
|
222 |
(2) |
|
|
Hyperthyroidism and Antithyroid Drugs |
|
|
224 |
(2) |
|
|
|
226 |
(4) |
|
|
|
226 |
(1) |
|
|
Pharmacodynamic Therapy with Glucocorticoids |
|
|
226 |
(4) |
|
|
Androgens. Anabolic Steroids, Antiandrogens |
|
|
230 |
(2) |
|
|
|
230 |
(2) |
|
|
Follicular Growth and Ovulation, Estrogen and Progestin Production |
|
|
232 |
(2) |
|
|
|
234 |
(2) |
|
|
Antiestrogen and Antiprogestin Active Principles |
|
|
236 |
(2) |
|
|
|
238 |
(2) |
|
|
|
240 |
(2) |
|
|
Variations in Dosage Form |
|
|
240 |
(1) |
|
|
Variation in Amino Acid Sequence |
|
|
240 |
(2) |
|
|
Treatment of Insulin-dependent Diabetes Mellitus |
|
|
242 |
(2) |
|
|
|
242 |
(2) |
|
|
Treatment of Type II Diabetes Mellitus |
|
|
244 |
(2) |
|
|
|
246 |
(2) |
|
|
Drugs for Maintaining Calcium Homeostasis |
|
|
248 |
(2) |
|
|
|
250 |
(1) |
|
|
Drugs for Treating Bacterial Infections |
|
|
250 |
(2) |
|
|
Inhibitors of Cell Wall Synthesis |
|
|
252 |
(4) |
|
|
|
256 |
(1) |
|
|
Inhibitors of Tetrahydrofolate Synthesis |
|
|
256 |
(2) |
|
|
Inhibitors of DNA Function |
|
|
258 |
(2) |
|
|
Inhibitors of Protein Synthesis |
|
|
260 |
(4) |
|
|
Drugs for Treating Mycobacterial Infections |
|
|
264 |
(2) |
|
|
|
264 |
(1) |
|
|
|
264 |
(2) |
|
|
|
266 |
(1) |
|
|
Drugs Used in the Treatment of Fungal Infections |
|
|
266 |
(2) |
|
|
|
268 |
(1) |
|
|
Pharmacotherapy of Viral Infections |
|
|
268 |
(4) |
|
|
Drugs for the Treatment of HIV |
|
|
272 |
(2) |
|
|
Inhibitors of Reverse Transcriptase---Nucleoside Agents |
|
|
272 |
(1) |
|
|
|
272 |
(1) |
|
|
|
272 |
(1) |
|
|
|
272 |
(2) |
|
|
|
274 |
(1) |
|
|
Drugs for Treating Endoparasitic and Ectoparasitic Infestations |
|
|
274 |
(2) |
|
|
|
276 |
(2) |
|
|
|
278 |
(2) |
|
|
|
280 |
(1) |
|
|
Chemotherapy of Malignant Tumors |
|
|
280 |
(4) |
|
|
Interference with Cell Proliferation Signaling Pathways |
|
|
284 |
(2) |
|
|
Special Antineoplastic Drug Actions |
|
|
286 |
(1) |
|
|
Mechanisms of Resistance to Cytostatics |
|
|
286 |
(2) |
|
|
|
288 |
(1) |
|
|
Inhibition of Immune Responses |
|
|
288 |
(2) |
|
|
Calcineurin Inhibitors. Sirolimus |
|
|
290 |
(2) |
|
|
|
292 |
(1) |
|
|
Inhibitors of Leukocyte Migration |
|
|
292 |
(2) |
|
|
Antidotes and Treatment of Poisonings |
|
|
294 |
(4) |
|
|
|
298 |
(1) |
|
|
Psychotomimetics (Psychedelics, Hallucinogens) |
|
|
298 |
(2) |
|
|
|
300 |
(1) |
|
|
Localization of Nicotinic ACh Receptors |
|
|
300 |
(1) |
|
|
Effects of Nicotine on Body Function |
|
|
300 |
(1) |
|
|
Aids for Smoking Cessation |
|
|
300 |
(2) |
|
|
Consequences of Tobacco Smoking |
|
|
302 |
(2) |
|
|
|
304 |
(3) |
|
|
Therapy of Selected Diseases |
|
|
307 |
(42) |
|
|
|
308 |
(2) |
|
|
|
310 |
(2) |
|
|
|
312 |
(2) |
|
|
Acute Coronary Syndrome---Myocardial Infarction |
|
|
314 |
(2) |
|
|
|
316 |
(2) |
|
|
|
318 |
(2) |
|
|
|
320 |
(2) |
|
|
|
322 |
(4) |
|
|
|
326 |
(2) |
|
|
|
328 |
(2) |
|
|
Sleep Disorders and Hypnotics |
|
|
330 |
(2) |
|
|
Local Treatment of Glaucoma |
|
|
332 |
(2) |
|
|
|
334 |
(2) |
|
|
|
336 |
(2) |
|
|
Obesity---Sequelae and Therapeutic Approaches |
|
|
338 |
(2) |
|
|
Atopy and Antiallergic Therapy |
|
|
340 |
(2) |
|
|
|
342 |
(2) |
|
|
|
344 |
(2) |
|
|
Chronic Inflammatory Bowel Disease |
|
|
346 |
(3) |
|
|
|
349 |
(2) |
|
|
|
351 |
(22) |
|
|
|
352 |
(11) |
|
|
|
363 |
(10) |
|
Subject Index |
|
373 |
|
